Cure8 research brief
RDW is part of a routine complete blood count and, if reliably associated with IBD activity, could offer a low-cost, widely available adjunctive biomarker for detecting disease and monitoring activity.
Clinicians, IBD researchers, adult patients and caregivers interested in noninvasive biomarkers and blood-test monitoring
The paper pooled data from multiple studies and found elevated RDW in Crohn’s disease and ulcerative colitis compared with controls, and higher RDW in active versus inactive disease. The authors highlight RDW as an inexpensive, widely available biomarker that showed moderate-to-good diagnostic performance in pooled analyses.
RDW would be considered alongside other clinical information and tests (symptoms, CRP, fecal calprotectin, endoscopy) rather than as a sole diagnostic tool. Details such as exact pooled effect sizes, study heterogeneity, and the types of populations studied are important to review in the full paper before applying findings to individual care.
This summary is based on the article abstract and pooled analysis reported by the authors. RDW is a non-specific marker and can be affected by anemia and other conditions; clinical use would require considering other tests and patient context. Review the full paper for details on study quality, populations, and heterogeneity before changing practice.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The review suggests RDW, an inexpensive and widely available blood test parameter, is higher in IBD and correlates with disease activity—meaning it might help clinicians monitor disease alongside other tests.
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.
Blood markers that correlate with endoscopic healing could help track inflammation noninvasively and may reduce the frequency of endoscopy if validated. For people with IBD, better blood-based tools could make monitoring...
